A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Inosine

Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

The Salah Foundation

OTHER

collaborator

Sean M. Healey & AMG Center for ALS

OTHER

lead

Massachusetts General Hospital

OTHER

NCT02288091 - A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter